Does Medicare Advantage Cover Enclomiphene Citrate?

Why Medicare Advantage Plans Exclude Enclomiphene Citrate

Medicare Advantage (MA) plans follow the same formulary rules as original Medicare Part D for outpatient prescription drugs. A drug must hold active FDA approval to qualify for routine Part D inclusion under CMS coverage determination guidelines [1]. Enclomiphene citrate, the trans-isomer of clomiphene, was developed by Repros Therapeutics under the brand name Androxal but never completed the FDA approval process [2]. Two Phase III trials (ZA-304 and ZA-305) showed that enclomiphene raised testosterone to eugonadal levels in men with secondary hypogonadism, yet the FDA issued a Complete Response Letter citing the need for additional data [3].

Because no manufacturer holds an active New Drug Application (NDA) for enclomiphene citrate, it exists in a regulatory gray zone. The compound is currently available only through 503A and 503B compounding pharmacies under physician prescription [4]. CMS policy is explicit: compounded drugs are generally excluded from Part D coverage unless they contain at least one FDA-approved active ingredient used in a medically accepted indication listed in an approved compendium [5]. Enclomiphene as a single-entity compound does not meet this threshold. That single regulatory gap explains nearly every coverage denial.

How Part D Formulary Tiers Work for Off-Label Drugs

MA plans organize drugs into formulary tiers that determine cost-sharing. Tier 1 holds preferred generics (lowest copay), while specialty tiers carry the highest out-of-pocket burden [6]. For a drug to land on any tier, the plan's Pharmacy and Therapeutics committee must evaluate it against CMS-accepted compendia, including the American Hospital Formulary Service Drug Information (AHFS-DI) and DrugDex [7].

Enclomiphene citrate is absent from these compendia as a distinct molecular entity. Clomiphene citrate, the racemic mixture containing both enclomiphene (trans) and zuclomiphene (cis) isomers, does appear in AHFS-DI with a recognized off-label use for male hypogonadism [8]. This distinction matters. A physician who prescribes "clomiphene citrate 25 mg" may secure Part D coverage at Tier 1 or Tier 2 on many MA formularies, while a prescription written specifically for "enclomiphene citrate 25 mg" will be rejected at the pharmacy counter. The formulary search tools on Medicare.gov confirm this: entering clomiphene citrate returns results across hundreds of plans, while enclomiphene citrate returns zero [9].

Prior Authorization and Step Therapy: What to Expect

Prior authorization (PA) is a utilization management tool that MA plans use to control costs and verify medical necessity before dispensing a medication [10]. Step therapy requires a patient to try and fail a lower-cost drug before the plan approves a more expensive alternative. Neither mechanism applies to enclomiphene in a meaningful way, because the drug is simply not on formulary.

If a prescriber submits a PA request for enclomiphene citrate, the plan will issue a denial based on non-formulary status rather than clinical criteria. The denial letter will typically reference 42 CFR §423.120, which limits Part D coverage to drugs that can be dispensed by a licensed pharmacy under a valid prescription for an FDA-approved or compendium-supported indication [11]. Step therapy protocols in the MA hypogonadism space do exist, but they govern access to testosterone replacement products like testosterone cypionate injections and topical gels, not selective estrogen receptor modulators (SERMs) [12].

One narrow exception deserves mention. Some MA plans with supplemental benefits have experimented with expanded formularies that include select compounded medications. These are rare, plan-specific, and typically restricted to compounds with strong compendium support [13]. A call to the plan's pharmacy benefit manager can clarify whether any such exception exists in a given contract year.

The Clinical Case for Enclomiphene in Male Hypogonadism

Enclomiphene citrate acts as a selective estrogen receptor antagonist at the hypothalamus and pituitary, blocking negative feedback from estradiol and thereby increasing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion [14]. This mechanism raises endogenous testosterone production without suppressing spermatogenesis, a property that distinguishes it from exogenous testosterone therapy.

Kim et al. published a 2016 study in BJU International examining enclomiphene in men with secondary hypogonadism. The trial demonstrated that enclomiphene 25 mg daily raised total testosterone from a mean baseline of 228 ng/dL to 419 ng/dL at 16 weeks, while simultaneously maintaining or improving sperm parameters [15]. A separate analysis of the ZA-303 trial (N=124) found that enclomiphene normalized testosterone in 85% of treated men compared to 12% receiving placebo [16]. The Endocrine Society's 2018 clinical practice guideline on testosterone therapy in men with hypogonadism acknowledges clomiphene citrate as an off-label option for men who wish to preserve fertility, though the guideline does not specifically address the isolated trans-isomer [17].

These data explain why prescribers are interested in enclomiphene. The drug offers testosterone restoration without the fertility trade-off that accompanies exogenous testosterone. For men on Medicare who are managing hypogonadism and still wish to preserve reproductive function, enclomiphene fills a clinical gap. The problem is purely regulatory and financial, not scientific.

How to Appeal a Medicare Advantage Denial

MA beneficiaries have a structured, multi-level appeals process codified under 42 CFR Part 422, Subpart M [18]. The process works as follows.

Level 1: Plan Redetermination. The enrollee or prescriber files a written appeal within 60 days of the denial. The plan must respond within 7 days for standard requests or 72 hours for expedited requests. Include a letter of medical necessity from the prescribing physician, relevant lab work (total testosterone, LH, FSH, estradiol), and peer-reviewed literature supporting enclomiphene use [19].

Level 2: Independent Review Entity (IRE). If the plan upholds the denial, the case moves to MAXIMUS Federal Services, the CMS-contracted IRE. MAXIMUS reviews the clinical evidence independently. The threshold for reversal is whether the drug meets a "medically accepted indication" under a CMS-recognized compendium [20].

Level 3 and beyond. Further appeals proceed to an Administrative Law Judge (for claims exceeding $190 in 2026), the Medicare Appeals Council, and ultimately federal district court [21].

Realistically, appeals for enclomiphene citrate face long odds. The absence of FDA approval and compendium listing as a standalone agent means the clinical evidence, however strong, does not satisfy the regulatory criteria that adjudicators apply. A prescriber willing to switch the prescription to racemic clomiphene citrate will achieve coverage far more quickly than the appeals process can deliver.

Manufacturer Savings Cards and Medicare: A Legal Barrier

Federal anti-kickback statutes (42 USC §1320a-7b) prohibit pharmaceutical manufacturers from offering copay assistance, discount cards, or savings programs to Medicare beneficiaries [22]. This applies to Part D, MA-PD, and any Medicare-linked drug benefit. The Office of Inspector General (OIG) has issued multiple advisory opinions confirming that manufacturer copay cards used by Medicare enrollees constitute illegal remuneration [23].

Because enclomiphene citrate is produced by compounding pharmacies rather than a single branded manufacturer, no manufacturer savings card program exists in the traditional sense. Some compounding pharmacies offer membership or subscription pricing models that reduce per-month costs to $30 to $60. These programs are not manufacturer copay cards and do not violate the anti-kickback statute, because they represent direct pharmacy pricing rather than third-party subsidies [24]. Medicare beneficiaries can legally use these pharmacy pricing programs.

Practical Alternatives for Medicare Advantage Enrollees

The most direct workaround is a prescription for racemic clomiphene citrate (Clomid). Generic clomiphene 50 mg tablets are on the formulary of the vast majority of Part D plans at Tier 1, with copays typically between $0 and $15 for a 30-day supply [25]. Prescribers commonly start men at 25 mg every other day or 25 mg daily, titrating based on testosterone and estradiol response. A 2015 meta-analysis in the Journal of Sexual Medicine covering 11 studies and 1,438 men found that clomiphene citrate increased total testosterone by an average of 292 ng/dL from baseline, with improvements in hypogonadal symptoms and sexual function scores [26].

The difference between racemic clomiphene and enclomiphene is the presence of zuclomiphene, the cis-isomer. Zuclomiphene has a longer half-life (approximately 30 days versus 10 hours for enclomiphene) and exhibits weak estrogenic agonist activity that some clinicians believe contributes to side effects including visual disturbances and mood changes [27]. Whether this translates to a clinically meaningful disadvantage at the low doses used in male hypogonadism remains debated. No head-to-head trial comparing clomiphene 25 mg versus enclomiphene 25 mg for male hypogonadism has been published in a peer-reviewed journal as of May 2026.

Other covered alternatives include testosterone cypionate injections (Tier 1 to Tier 2 on most plans), topical testosterone gels such as AndroGel or its generic equivalents, and nasal testosterone (Natesto) [28]. Each of these suppresses spermatogenesis to varying degrees, which limits their use in men prioritizing fertility. Human chorionic gonadotropin (hCG) is another off-label option for maintaining intratesticular testosterone, though CMS coverage for hCG in this indication varies by plan [29].

Cost Comparison: Out-of-Pocket Enclomiphene vs. Covered Alternatives

For MA beneficiaries weighing their options, cost is often the deciding factor. Compounded enclomiphene citrate 25 mg runs $30 to $90 per month depending on the pharmacy, quantity, and whether the patient uses a telehealth subscription service [30]. Generic clomiphene citrate 25 mg through a Part D plan costs $0 to $15 per month at most preferred pharmacies. Testosterone cypionate 200 mg/mL (10 mL vial) carries a Part D copay of $5 to $30, lasting 5 to 10 weeks depending on dosing [31].

The cost gap between out-of-pocket enclomiphene and covered clomiphene is modest enough that many patients absorb it willingly, particularly if they have experienced side effects attributed to the zuclomiphene isomer. The American Urological Association does not formally recommend one over the other, noting that clomiphene citrate (racemic) carries the strongest evidence base in this off-label application [32].

When Enclomiphene Coverage May Change

Two developments could shift the coverage picture. First, if a manufacturer successfully completes the NDA process for enclomiphene citrate, FDA approval would open the door to formulary inclusion on Part D plans within one to two formulary update cycles [33]. As of May 2026, no active NDA for enclomiphene is listed in the FDA's publicly available database at accessdata.fda.gov [34].

Second, the CMS Innovation Center has explored models that expand Part D coverage for compounded medications meeting specific quality and safety standards under section 503B of the Federal Food, Drug, and Cosmetic Act [35]. Any broadening of compounding coverage policy could indirectly benefit enclomiphene access for Medicare beneficiaries. Beneficiaries and prescribers should monitor the annual Part D formulary update notices, published each September, for changes to their specific plan.

Men currently taking enclomiphene citrate through a compounding pharmacy should have their testosterone, LH, estradiol, and hematocrit checked every 6 to 12 months per Endocrine Society monitoring recommendations for SERM-based hypogonadism management [17].